Epoxide Linker Synthesis for Bisphosphonate Fluorescent Labeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for fluorescently labeling bone-targeting nitrogen-containing bisphosphonate drugs, especially those lacking a primary amine group, face challenges in forming stable conjugates due to the lack of a primary amine for reaction, which affects their ability to retain bone affinity and stability.
Innovation Solution
A novel linking strategy involving the reaction of N-t-BOC protected 1,2-epoxy-3-aminopropane with the nitrogen of bisphosphonate compounds, allowing for the introduction of a primary amine and a permanent positive charge, enabling facile conjugation with fluorescent labels like 5- or 6-carboxyfluorescein under mild conditions, thereby maintaining bone affinity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a primary amine group is introduced to enable fluorescent labeling, then the ability to form stable amide bonds with fluorescent labels is improved, but the bone affinity of the bisphosphonate compound may be reduced
Solution Approach 1:
The molecule is divided into distinct functional segments: the bisphosphonate core structure that maintains bone affinity, and the introduced amine-containing side chain that enables fluorescent labeling. This segmentation allows each part to fulfill its specific function independently.
Solution Approach 2:
The amine group is introduced at a specific location on the bisphosphonate molecule (at the R1 or R2 positions) rather than modifying the core bisphosphonate structure. This localized modification ensures that the bone-targeting capability of the bisphosphonate moiety is preserved while providing the necessary amine for stable amide bond formation with fluorescent labels.
2Reliability
If acylation is used to conjugate fluorescent labels, then stable amide bonds are formed, but the basicity of the nitrogen atom is reduced and its ability to acquire positive charge is abolished
Solution Approach 1:
The nitrogen atom is segmented into two functional roles: one nitrogen (in the bisphosphonate core) maintains basicity and charge acquisition capability for bone targeting, while another nitrogen (in the introduced amine side chain) undergoes acylation to form the stable amide bond with the fluorescent label.
Solution Approach 2:
The introduced amine side chain acts as an intermediary that provides the reactive amine group for amide bond formation without compromising the basicity of the core bisphosphonate nitrogen. This intermediary structure enables both functions: stable conjugation and maintenance of bone affinity.
3Ease of manufacture
If structural modification is made to enable labeling, then the ability to form conjugates is improved, but the pharmacological properties of the original drug may be altered
Solution Approach 1:
The structural modification is localized to the side chains (R1 or R2 positions) of the bisphosphonate molecule, leaving the core pharmacophore structure intact. This ensures that the pharmacological properties determined by the bisphosphonate core are preserved while enabling fluorescent labeling through the modified side chain.
Solution Approach 2:
The amine-containing side chain is pre-introduced into the bisphosphonate structure before conjugation with the fluorescent label. This preliminary action prepares the molecule for stable amide bond formation while maintaining the original pharmacological characteristics of the bisphosphonate core.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the synthesis of fluorescently labeled bisphosphonate compounds with improved solubility and stability, allowing for effective visualization and study of bone diseases while retaining the compounds' pharmacological properties.
Implementation Method 1
reaction of N-t-BOC protected 1,2-epoxy-3-aminopropane with the nitrogen of bisphosphonate compounds, allowing for the introduction of a primary amine
Implementation Method 2
forming an amide bond between the label and drug/protein
Data Source
AI summary
The present invention relates to drug derivatives and linkers. The invention specifically relates to compounds and methods of phosphonates and linkers, that are useful as carriers for imaging agents and useful in the treatment of various bone diseases.